DECEMBER 6–10, 2022
Henry B. Gonzalez Convention Center
San Antonio, TX
Wednesday’s General Session featured new data about the oral SERD elacestrant and the effect of tamoxifen on uterine cancer risk.
Olufunmilayo I. Olopade, MD, FAACR, recounted her lifelong journey through breast cancer genomics during the William L. McGuire Memorial Lecture on Wednesday.
A special session on Wednesday reviewed the Food and Drug Administration’s recent approval of pembrolizumab for neoadjuvant and adjuvant treatment, and abemaciclib in the adjuvant setting.
Subscribe to get regular news updates from SABCS.org and SABCS Meeting News.